Want to see PMI full AI Analyst Report?
PMI Stock Chart & Stats
$1.82
--
Market closed
$1.82
--
Day’s Range― - ―
52-Week Range$0.11 - $13.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)26.64M
Market Cap
$16.43M
Enterprise Value$300.41M
Total Cash (Recent Filing)$121.00K
Total Debt (Recent Filing)$3.27M
Price to Earnings (P/E)―
Beta-2.12
Next Earnings
Sep 21, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding102,695,940
10 Day Avg. Volume56,270,999
30 Day Avg. Volume26,644,921
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)34.04
Price to Sales (P/S)26.11
P/FCF Ratio-8.23
Enterprise Value/Market Cap18.28
Enterprise Value/Revenue54.85
Enterprise Value/Gross Profit360.64
Enterprise Value/Ebitda-12.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sole FDA‑approved Total Artificial HeartPicard owns and commercializes the only FDA‑ and Health Canada‑approved total artificial heart with ~2,100 implants across 27 countries. That exclusive regulatory position and installed base create durable demand for device implants, driver rentals and consumables, supporting long‑term revenue and commercial leverage as donor shortages persist.
Top-line Growth And Margin ImprovementRevenue growth and a swing from negative to positive gross margins reflect improving product mix, pricing and operational execution. Sustained top-line momentum plus expanding gross margin increases the odds the company can scale toward fixed cost absorption and narrow operating losses if commercial traction and cost controls persist.
Debt Reduction And Recent Equity FinancingMaterial reduction in senior secured debt alongside a $5M equity raise meaningfully eases near‑term leverage and refinancing pressure. Lower secured obligations and fresh capital improve runway and give management flexibility to invest in commercialization and the Emperor development program while addressing listing compliance.
Bears Say
Large, Persistent Cash BurnThe company consumes significant cash each year, with deeply negative operating and free cash flows. Persistent cash burn forces continued external financing, increases dilution risk, and constrains investment in R&D and commercialization until structural profitability or sustained margin expansion is achieved.
Negative Equity And Exchange Noncompliance RiskNegative equity and formal NYSE American noncompliance notices signal weakened solvency and raise the specter of delisting if remediation fails. That structural governance and capital‑structure risk can materially increase cost of capital, limit financing options, and impair long‑term strategic initiatives.
Recent CEO Departure And Leadership TransitionLeadership change during a critical phase—regulatory roadmap, product development and listing remediation—creates execution risk. While the interim CEO has relevant device experience, the CEO search and transition can delay strategic decisions, hamper stakeholder confidence, and complicate timely execution of long‑range plans.
Picard Medical, Inc. News
PMI FAQ
What was Picard Medical, Inc.’s price range in the past 12 months?
Picard Medical, Inc. lowest stock price was $0.11 and its highest was $13.68 in the past 12 months.
What is Picard Medical, Inc.’s market cap?
Picard Medical, Inc.’s market cap is $16.43M.
When is Picard Medical, Inc.’s upcoming earnings report date?
Picard Medical, Inc.’s upcoming earnings report date is Sep 21, 2026 which is in 64 days.
How were Picard Medical, Inc.’s earnings last quarter?
Picard Medical, Inc. released its earnings results on May 21, 2026. The company reported -$0.1 earnings per share for the quarter, the consensus estimate of -$0.1 by $0.
Is Picard Medical, Inc. overvalued?
According to Wall Street analysts Picard Medical, Inc.’s price is currently Overvalued.
Does Picard Medical, Inc. pay dividends?
Picard Medical, Inc. does not currently pay dividends.
What is Picard Medical, Inc.’s EPS estimate?
Picard Medical, Inc.’s EPS estimate is -0.03.
How many shares outstanding does Picard Medical, Inc. have?
Picard Medical, Inc. has 102,695,940 shares outstanding.
What happened to Picard Medical, Inc.’s price movement after its last earnings report?
Picard Medical, Inc. reported an EPS of -$0.1 in its last earnings report, expectations of -$0.1. Following the earnings report the stock price went down -8.442%.
Which hedge fund is a major shareholder of Picard Medical, Inc.?
Currently, no hedge funds are holding shares in PMI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Picard Medical, Inc.
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
PMI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Aethlon Medical
―
―
Catheter Precision
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
―
Insiders
0.10% Mutual Funds
0.04% Other Institutional Investors
97.41% Public Companies and
Individual Investors